The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Published version of a preprint
Abstract
Targeting p53 by the small-molecule PRIMA-1Met/APR-246 has shown promising preclinical activity in various cancer types. However, the mechanism of PRIMA-1Met–induced apoptosis is not completely understood and its effect on multiple myeloma cells is unknown. In this study, we evaluated antitumor effect of PRIMA-1Met alone or its combination with current antimyeloma agents in multiple myeloma cell lines, patient samples, and a mouse xenograft model. Results of our study showed that PRIMA-1Met decreased the viability of multiple myeloma cells irrespective of p53 status, with limited cytotoxicity toward normal hematopoietic cells. Treatment of multiple myeloma cells with PRIMA-1Met resulted in induction of apoptosis, inhibition of colony formation, and migration. PRIMA-1Met restored wild-type conformation of mutant p53 and induced activation of p73 upregulating Noxa and downregulating Mcl-1 without significant modulation of p53 level. siRNA-mediated silencing of p53 showed a little effect on apoptotic response of PRIMA-1Met, whereas knockdown of p73 led to substantial attenuation of apoptotic activity in multiple myeloma cells, indicating that PRIMA-1Met–induced apoptosis is, at least in part, p73–dependent. Importantly, PRIMA-1Met delayed tumor growth and prolonged survival of mice bearing multiple myeloma tumor. Furthermore, combined treatment of PRIMA-1Met with dexamethasone or doxorubicin displayed synergistic effects in both multiple myeloma cell lines and primary multiple myeloma samples. Consistent with our in vitro observations, cotreatment with PRIMA-1Met and dexamethasone resulted in enhanced antitumor activity in vivo. Our study for the first time shows antimyeloma activity of PRIMA-1Met and provides the rationale for its clinical evaluation in patients with multiple myeloma, including the high-risk group with p53 mutation/deletion. Mol Cancer Ther; 12(11); 2331–41. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibits the growth of p53 mutant tumors of various origins in combination with other anticancer drugs.390–396”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [391]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 2×
“1A), is being tested in phase I/II clinical trials (29).”
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
Research works printed but not linked: 36
- Anderson, 2011, Pathogenesis of myeloma, Annu Rev Pathol, 6, 249, 10.1146/annurev-pathol-011110-130249 · DOI · Paper page
- Barille-Nion, 2003, Advances in biology and therapy of multiple myeloma, Hematology Am Soc Hematol Educ Program, 248, 10.1182/asheducation-2003.1.248 · DOI
- Barlogie, 2004, Treatment of multiple myeloma, Blood, 103, 20, 10.1182/blood-2003-04-1045 · DOI · Paper page
- Avet-Loiseau, 1999, p53 deletion is not a frequent event in multiple myeloma, Br J Haematol, 106, 717, 10.1046/j.1365-2141.1999.01615.x · DOI
- Chang, 2005, p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation, Blood, 105, 358, 10.1182/blood-2004-04-1363 · DOI · Paper page
- Chng, 2007, Clinical significance of TP53 mutation in myeloma, Leukemia, 21, 582, 10.1038/sj.leu.2404524 · DOI
- Reece, 2009, Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13, Blood, 114, 522, 10.1182/blood-2008-12-193458 · DOI · Paper page
- Jiang, 2012, Genomic stratification of multiple myeloma treated with novel agents, Leuk Lymphoma, 53, 202, 10.3109/10428194.2011.608449 · DOI
- Saha, 2010, Pharmacological activation of the p53 pathway in haematological malignancies, J Clin Pathol, 63, 204, 10.1136/jcp.2009.070961 · DOI
- Wiman, 2006, Strategies for therapeutic targeting of the p53 pathway in cancer, Cell Death Differ, 13, 921, 10.1038/sj.cdd.4401921 · DOI
- Wang, 2008, Restoration of p53 to limit tumor growth, Curr Opin Oncol, 20, 90, 10.1097/CCO.0b013e3282f31d6f · DOI
- Saha, 2010, MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity, Cancer Biol Ther, 9, 936, 10.4161/cbt.9.11.11882 · DOI
- Saha, 2010, Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways, Cancer Biol Ther, 10, 567, 10.4161/cbt.10.6.12535 · DOI
- Saha, 2010, RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses, Mol Cancer Ther, 9, 3041, 10.1158/1535-7163.MCT-10-0471 · DOI
- Saha, 2012, Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma, PLoS ONE, 7, e30215, 10.1371/journal.pone.0030215 · DOI
- Nahi, 2004, Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion, Br J Haematol, 127, 285, 10.1111/j.1365-2141.2004.05210.x · DOI · Paper page
- Rökaeus, 2007, PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins, Oncogene, 26, 982, 10.1038/sj.onc.1209858 · DOI
- Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038/onc.2009.425 · DOI
- Rökaeus, 2010, PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73, Oncogene, 29, 6442, 10.1038/onc.2010.382 · DOI
- Zandi, 2011, PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53, Clin Cancer Res, 17, 2830, 10.1158/1078-0432.CCR-10-3168 · DOI · Paper page
- Nahi, 2006, PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion, Br J Haematol, 132, 230, 10.1111/j.1365-2141.2005.05851.x · DOI
- Ali, 2011, APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells, Eur J Haematol, 86, 206, 10.1111/j.1600-0609.2010.01557.x · DOI · Paper page
- Bao, 2011, PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo, Cell Cycle, 10, 301, 10.4161/cc.10.2.14538 · DOI
- Supiot, 2008, PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status, Radiother Oncol, 86, 407, 10.1016/j.radonc.2008.01.001 · DOI
- Cory, 2006, Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis versus apoptosis, Anticancer Res, 26, 1289
- Trudel, 2007, The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan, Clin Cancer Res, 13, 621, 10.1158/1078-0432.CCR-06-1526 · DOI
- Di Martino, 2012, Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence, Clin Cancer Res, 18, 6260, 10.1158/1078-0432.CCR-12-1708 · DOI · Paper page
- Tai, 2012, Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma, Blood, 120, 1877, 10.1182/blood-2011-12-396853 · DOI · Paper page
- Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
- Alonso, 2009, Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM, Blood, 114, 1563, 10.1182/blood-2009-02-207654 · DOI
- Lu, 2008, Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73, Cancer Biol Ther, 7, 2039, 10.4161/cbt.7.12.7461 · DOI
- Kravchenko, 2008, Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway, Proc Natl Acad Sci U S A, 105, 6302, 10.1073/pnas.0802091105 · DOI · Paper page
- Irwin, 2003, Chemosensitivity linked to p73 function, Cancer Cell, 3, 403, 10.1016/S1535-6108(03)00078-3 · DOI · Paper page
- Podar, 2006, The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma, Proc Natl Acad Sci U S A, 103, 19478, 10.1073/pnas.0609329103 · DOI · Paper page
- Holien, 2012, Addiction to c-MYC in multiple myeloma, Blood, 120, 2450, 10.1182/blood-2011-08-371567 · DOI · Paper page
- Holien, 2012, Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC, Leukemia, 26, 1073, 10.1038/leu.2011.263 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & Müller, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 291
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology
Brown, R. A. M., Richardson, K. L., Kabir, T. D., Trinder, D., Ganss, R., & Leedman, P. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00476 · Cited by 278
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Metadata
- Authors
- Saha, M. N., Jiang, H., Yang, Y., Reece, D., & Chang, H.
- Affiliations
- Authors' Affiliations: 1Division of Molecular and Cellular Biology, Toronto General Research Institute; 2Department of Laboratory Medicine & Pathobiology, University of Toronto; 3Department of Laboratory Hematology; 4Department of Hematology and Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-11-01
- Volume
- 12
- Issue
- 11
- Pages
- 2331-2341
- ISSN
- 1535-7163
- 1538-8514
- Cited by
- 91
- References
- 7
- Language
- en
- Update notices
- correction (2018-04-30)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-1166
- The paper
- Saha, M. N., Jiang, H., Yang, Y., Reece, D., & Chang, H. (2013). PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-1166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.